128 related articles for article (PubMed ID: 14677619)
1. An open-label study of the effects of a 24-day regimen of gestodene 60 microg/ethinylestradiol 15 microg on endometrial histological findings in healthy women.
Oosterbaan HP
Eur J Contracept Reprod Health Care; 1999 Nov; 4 Suppl 2():3-8. PubMed ID: 14677619
[TBL] [Abstract][Full Text] [Related]
2. Cycle control, safety and efficacy of a 24-day regimen of gestodene 60 microg/ ethinylestradiol 15 microg and a 21-day regimen of desogestrel 150 microg/ethinylestradiol 20 microg.
Eur J Contracept Reprod Health Care; 1999 Nov; 4 Suppl 2():17-25. PubMed ID: 14677621
[TBL] [Abstract][Full Text] [Related]
3. The safety and contraceptive efficacy of a 24-day low-dose oral contraceptive regimen containing gestodene 60 microg and ethinylestradiol 15 microg.
Eur J Contracept Reprod Health Care; 1999 Nov; 4 Suppl 2():9-15. PubMed ID: 14677620
[TBL] [Abstract][Full Text] [Related]
4. A comparative study of the effects of gestodene 60 microg/ethinylestradiol 15 microg and desogestrel 150 microg/ethinylestradiol 20 microg on hemostatic balance, blood lipid levels and carbohydrate metabolism.
van der Mooren MJ; Klipping C; van Aken B; Helmerhorst E; Spielmann D; Kluft C
Eur J Contracept Reprod Health Care; 1999 Nov; 4 Suppl 2():27-35. PubMed ID: 14677622
[TBL] [Abstract][Full Text] [Related]
5. The effects of a low-dose gestodene-containing oral contraceptive on endometrial histology in healthy women.
Coenen CM; Hollanders JM; Rolland R; Spielmann D; Bulten J
Eur J Contracept Reprod Health Care; 1996 Dec; 1(4):325-9. PubMed ID: 9678115
[TBL] [Abstract][Full Text] [Related]
6. [Clinical study of a low-dose contraceptive--Femodene].
Rachev E; Damianov L; Dukovski A; Katsarova M
Akush Ginekol (Sofiia); 1995; 34(3):71-3. PubMed ID: 8787249
[TBL] [Abstract][Full Text] [Related]
7. Open, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day oral contraceptive regimen with 20 microg ethinyl estradiol and 75 microg gestodene and a 21-day regimen with 20 microg ethinyl estradiol and 150 microg desogestrel.
Endrikat J; Cronin M; Gerlinger C; Ruebig A; Schmidt W; Düsterberg B
Contraception; 2001 Sep; 64(3):201-7. PubMed ID: 11704101
[TBL] [Abstract][Full Text] [Related]
8. Endometrial safety of a novel monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24/4-day regimen over six cycles.
Rabe T; Hartschuh E; Wahlstrom T; Höschen K; König S
Contraception; 2010 Oct; 82(4):358-65. PubMed ID: 20851230
[TBL] [Abstract][Full Text] [Related]
9. A clinical overview of a new triphasic contraceptive containing gestodene.
Christie T
Int J Fertil; 1989 Sep; 34 Suppl():40-9. PubMed ID: 2576257
[TBL] [Abstract][Full Text] [Related]
10. Comparison of two monophasic oral contraceptives: gestodene/ethinyl estradiol versus desogestrel/ethinyl estradiol.
Benagiano G
Int J Fertil; 1989 Sep; 34 Suppl():31-9. PubMed ID: 2576255
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and acceptability of two monophasic oral contraceptives containing ethinylestradiol and either desogestrel or gestodene.
Halbe HW; de Melo NR; Bahamondes L; Petracco A; Lemgruber M; de Andrade RP; da Cunha DC; Guazelli CA; Baracat EC
Eur J Contracept Reprod Health Care; 1998 Sep; 3(3):113-20. PubMed ID: 9853201
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, cycle control and side-effects of two monophasic combination oral contraceptives: gestodene/ethinylestradiol and norgestimate/ethinylestradiol.
Affinito P; Monterubbianesi M; Primizia M; Regine V; Di Carlo C; Farace MJ; Petrillo G; Nappi C
Gynecol Endocrinol; 1993 Dec; 7(4):259-66. PubMed ID: 8147235
[TBL] [Abstract][Full Text] [Related]
13. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W
Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
[TBL] [Abstract][Full Text] [Related]
14. Body weight change during use of a monophasic oral contraceptive containing 20 microg ethinylestradiol and 75 microg gestodene with a comparison of the women who completed versus those who prematurely discontinued intake.
Endrikat J; Gerlinger C; Cronin M; Wessel J; Ruebig A; Rosenbaum P; Düsterberg B
Eur J Contracept Reprod Health Care; 2001 Dec; 6(4):199-204. PubMed ID: 11848649
[TBL] [Abstract][Full Text] [Related]
15. Clinical comparison of two low-dose oral contraceptives, Minulet and Mercilon, in women over 30 years of age.
Kirkman RJ; Pedersen JH; Fioretti P; Roberts HE
Contraception; 1994 Jan; 49(1):33-46. PubMed ID: 8137624
[TBL] [Abstract][Full Text] [Related]
16. A double-blind comparative study of the effects of a 23-day oral contraceptive regimen with 20 microg ethinyl estradiol and 75 microg gestodene and a 21-day regimen with 30 microg ethinyl estradiol and 75 microg gestodene on hemostatic variables, lipids, and carbohydrate metabolism.
Endrikat J; Klipping C; Gerlinger C; Ruebig A; Schmidt W; Holler T; Düsterberg B
Contraception; 2001 Oct; 64(4):235-41. PubMed ID: 11747873
[TBL] [Abstract][Full Text] [Related]
17. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance.
Endrikat J; Müller U; Düsterberg B
Contraception; 1997 Mar; 55(3):131-7. PubMed ID: 9115000
[TBL] [Abstract][Full Text] [Related]
18. A 12-month clinical investigation with a 24-day regimen containing 15 microg ethinylestradiol plus 60 microg gestodene with respect to hemostasis and cycle control.
Fruzzetti F; Genazzani AR; Ricci C; De Negri F; Bersi C; Carmassi F
Contraception; 2001 Jun; 63(6):303-7. PubMed ID: 11672551
[TBL] [Abstract][Full Text] [Related]
19. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
Cianci A; De Leo V
Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
[TBL] [Abstract][Full Text] [Related]
20. Comparative study on the acceptability of two modern monophasic oral contraceptive preparations: 30 microgram ethinyl estradiol combined with 150 microgram desogestrel or 75 microgram gestodene.
Zichella L; Sbrignadello C; Tomassini A; Di Lieto A; Montoneri C; Zarbo G; Mancone M; Pietrobattista P; Bertoli G; Perrone G
Adv Contracept; 1999; 15(3):191-200. PubMed ID: 11019950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
